Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 11/20 | 0.63 |
| ▸ | FNTB | P49356 | 11/20 | 0.63 |
| ▸ | HRAS | P01112 | 1/20 | 0.51 |
| ▸ | KRAS | P01116 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4694574 | 1.00 | FNTA (0.63) | FNTAFNTBHRASKRAS | |
| SCHEMBL4696711 | 0.99 | FNTA (0.64) | FNTAFNTBHRASKRAS | |
| SCHEMBL4696153 | 0.96 | FNTA (0.65) | FNTAFNTBHRASKRAS | |
| SCHEMBL4697627 | 0.93 | FNTA (0.70) | FNTAFNTB | |
| SCHEMBL4693727 | 0.88 | FNTA (0.64) | FNTAFNTBHRASKRAS | |
| SCHEMBL4695216 | 0.85 | FNTA (0.52) | FNTAFNTB | |
| SCHEMBL4696001 | 0.85 | FNTA (0.52) | FNTAFNTB | |
| SCHEMBL4697563 | 0.84 | FNTA (0.53) | FNTAFNTB | |
| SCHEMBL14289913 | 0.84 | FNTA (0.65) | FNTAFNTB | |
| SCHEMBL4693539 | 0.84 | FNTA (0.61) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1318994-B1 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORP (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1318994-B1 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORP (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1318994-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | Schering Corporation (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6506756-B2 | For treatment of allergies, inflammatory and central nervous system related diseases | SCHERING CORPORATION | 2003-01-14 | — | — | US | disclosed |
| US-20020086859-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | SCHERING CORPORATION | 2002-07-04 | — | — | US | disclosed |
| WO-2002024659-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTGONISTS | SCHERING CORPORATION (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086859-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | HRH3, HRH4, HRH2 | FNTA 4297/4885FNTB 4668/4885HRAS 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.